Plavix - 75 mg 28 Tablets

Prevention of manifestations of atherothrombosis in adult patients:

have had myocardial infarction;

ischemic stroke (start of treatment — after 7 days, but no later than 6 months after the onset) or who have been diagnosed with peripheral arterial disease (arterial disease and atherothrombosis of the vessels of the lower extremities);

with acute coronary syndrome; with acute coronary syndrome without S — T segment elevation (unstable angina pectoris or myocardial infarction without Q wave).

Prevention of atherothrombotic and thromboembolic events in AF. Clopidogrel in combination with ASA is indicated in adult patients with AF who have at least one risk factor for vascular events, who have contraindications to VKA treatment and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events, including stroke.

Tradename: Plavix

Plavix

Composition: Each tablet contains:

Clopidogrel 75mg

Auxiliary components:

microcrystalline cellulose (E460), mannitol (E421), macrogol 6000 (E1521), lowsubstituted hydroxypropyl cellulose (E463), hydrogenated castor oil, powder for a coating suspension like Opadry 32K 14834 (lactose, hypromellose (E464), titanium dioxide (E 171), titanium dioxide E 1518), iron oxide red (E 172)), Carnauba wax.

Properties: Clopidogrel is a prodrug, one of the metabolites of which is an inhibitor of platel aggregation. Clopidogrel must be metabolized by CYP2C19 enzymes to form an active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor P2Y12 and the subsequent ADP-mediated activation of the GPIlb / Illa glycoprotein complex, thereby preventing platelet aggregation. Due to the irreversibility of binding, the exposed platelets are damaged for the rest of their life

(approximately 7-10 days), and the restoration of normal platelet function occurs at a rate corresponding to the platelet cycle.

Indications: Prevention of manifestations of atherothrombosis in adult patients:

have had myocardial infarction; ischemic stroke (start of treatment — after 7 days, but no later than 6 months after onset) or who have been diagnosed with peripheral arterial disease (arterial disease and atherothrombosis of the vessels of the lower extremities); with acute coronary syndrome; with acute coronary syndrome without S — T segment elevation (unstable angina pectoris or myocardial infarction without Q wave).

Prevention of atherothrombotic and thromboembolic events in AF. Clopidogrel in combination with ASA is indicated in adult patients with AF who have at least one risk factor for vascular events, who have contraindications to VKA treatment and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events, including stroke.

Method of administration and dosage: Before using the drug, consultation with a doctor is required.

Plavix is prescribed 75 mg 1 time / day, regardless of food intake.

In patients with ACS without ST-segment elevation, treatment with Plavix should be started with a single dose of 300 mg, and then continued with a dose of 75 mg / day in combination with acetylsalicylic acid at a dose of 75-325 mg / day.

Dose adjustment of Plavix in elderly patient patients with renal insufficiency is not requi

The course of treatment is prescribed by a doctor.

Contraindications: — hypersensitivity; — severe hepatic impairment; — acute bleeding; — pregnancy and lactation period; — children under 18 years old.

Precautions: Due to the risk of bleeding and hematological adverse reactions during treatment, if clinical symptoms indicating bleeding appear, a complete blood count and / or other appropriate tests should be performed immediately. As well as other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding associated with trauma, surgical or other pathological conditions, as well as in patients treated with ASA, heparin,

glycoprotein 11b / Illa inhibitors or non-steroidal anti-inflammatory drugs (NSAlDs), including COX-2 inhibitors or selective serotonin reuptake inhibitors (SSRls).

Side effects: Bleeding is the most common reaction reported both in clinical trials and in the postmarketing period, where it was recorded mainly in the first month of treatment.

Storage method: At a temperature of 15 to 30 degrees.

Packaging: The cardboard box holds tablets, paper instructions.